On this page

Halog

Halcinonide Cream · Cream

Prescription NDA TE AB RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Halog
Generic name
Halcinonide Cream
Dosage form
Cream
Route
Topical
Marketing category
NDA · NDA
Labeler
Genus Lifesciences Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
5
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Halcinonide 1 mg/g 310669 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
7

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
017556
Application type
NDA · New Drug Application
Approval date
November 27, 1974
Sponsor
SUN PHARM INDS INC
Products on application
1
Submissions recorded
29
Products approved under application 017556.
Product Trade name Form Strength Ingredient Status TE Flags
017556-001 HALOG CREAM HALCINONIDE Prescription AB RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
Yes
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 017556.
Type No. Action Status Date Review
Supplement 41 Manufacturing (CMC) Approved April 2, 2014 Standard
Supplement 38 Manufacturing (CMC) Approved June 10, 2009 N/A
Supplement 34 Labeling Approved September 29, 2004 Standard
Supplement 33 Manufacturing (CMC) Approved June 29, 1990 Standard
Supplement 32 Manufacturing (CMC) Approved June 27, 1989 Standard
Supplement 31 Manufacturing (CMC) Approved March 23, 1989 Standard
Supplement 30 Manufacturing (CMC) Approved November 3, 1987 Standard
Supplement 29 Manufacturing (CMC) Approved May 27, 1986 Standard
Supplement 28 Manufacturing (CMC) Approved April 22, 1986 Standard
Supplement 27 Manufacturing (CMC) Approved July 30, 1985 Standard
Supplement 26 Manufacturing (CMC) Approved January 28, 1985 Standard
Supplement 25 Manufacturing (CMC) Approved May 24, 1984 Standard
Supplement 23 Labeling Approved November 26, 1982 —
Supplement 24 Manufacturing (CMC) Approved March 18, 1982 Standard
Supplement 22 Manufacturing (CMC) Approved May 20, 1980 Standard
Supplement 21 Manufacturing (CMC) Approved March 24, 1980 Standard
Supplement 19 Labeling Approved February 13, 1980 —
Supplement 18 Manufacturing (CMC) Approved February 2, 1979 Standard
Supplement 17 Manufacturing (CMC) Approved January 10, 1979 Standard
Supplement 16 Labeling Approved June 7, 1978 —
Supplement 15 Manufacturing (CMC) Approved June 7, 1978 Standard
Supplement 13 Manufacturing (CMC) Approved April 19, 1978 Standard
Supplement 12 Manufacturing (CMC) Approved January 9, 1978 Standard
Supplement 11 Manufacturing (CMC) Approved August 24, 1977 Standard
Supplement 8 Labeling Approved March 8, 1977 —
Supplement 7 Manufacturing (CMC) Approved February 9, 1976 Standard
Supplement 3 Manufacturing (CMC) Approved May 7, 1975 Standard
Supplement 4 Labeling Approved April 4, 1975 —
Original application 1 Type 1 - New Molecular Entity Approved November 27, 1974 Standard

Review documents

  • 0 · Supplement · June 22, 2009
  • 0 · Supplement · June 16, 2009
  • 0 · Supplement · October 4, 2004
  • 0 · Supplement · October 4, 2004

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260115). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260115 HUMAN PRESCRIPTION DRUG · 20190107

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE HALOG (Halcinonide Cream, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION SECTION Apply the 0.1% HALOG (Halcinonide Cream, USP) to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the non-porous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply HALOG under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Description

openFDA Drug Labeling

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include halcinonide. Halcinonide, USP is designated chemically as 21-Chloro-9-fluoro-11β, 16α, 17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. Graphic formula: Each gram of 0.1% HALOG (Halcinonide Cream, USP) contains 1 mg halcinonide, USP in a specially formulated cream base consisting of cetyl alcohol, dimethicone 350, glyceryl monostearate, isopropyl palmitate, polysorbate 60, propylene glycol, purified water, and titanium dioxide. struture

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED HALOG ® (Halcinonide Cream, USP) 0.1% is smooth, soft homogeneous white to off-white cream, essentially free of foreign matter and is supplied as: NDC 10631-094-30 Tubes containing 60 g NDC 10631-094-76 Jar containing 216 g NDC 10631-094-71 Carton containing 240 g (4 tubes of 60g)

Adverse event reports

Source: openFDA FAERS
193
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HALCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
64950-126-06 64950-126 Genus Lifesciences Inc. 1 TUBE in 1 CARTON (64950-126-06) / 60 g in 1 TUBE January 13, 2026
10631-094-20 10631-094 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (10631-094-20) / 30 g in 1 TUBE February 10, 2009
10631-094-30 10631-094 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (10631-094-30) / 60 g in 1 TUBE February 10, 2009
10631-094-71 10631-094 Sun Pharmaceutical Industries, Inc. 4 TUBE in 1 CARTON (10631-094-71) / 60 g in 1 TUBE July 2, 2018
10631-094-76 10631-094 Sun Pharmaceutical Industries, Inc. 216 g in 1 JAR (10631-094-76) February 10, 2009
64950-126 64950-126 Genus Lifesciences Inc. — January 13, 2026
10631-094 10631-094 Sun Pharmaceutical Industries, Inc. — February 10, 2009

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.